MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13287-025-04289-3

Медицинская библиотека · Stem cell research & therapy · 2025

Consecutive intrabronchial administration of Wharton's jelly-derived mesenchymal stromal cells in ECMO-supported pediatric patients with end-stage interstitial lung disease: a safety and feasibility study (CIBA method).

Dominguez-Pinilla Nerea, González-Granado Luis Ignacio, Gonzaga Aitor, López Diaz María, Castellano Yáñez Cecilia, Aymerich Clara, Freire Xabier, Ordoñez Olga, Diaz de Atauri Álvaro Gimeno, Albi Rodríguez María Salomé, Martínez López Elisa, Iñiguez Rodrigo, Serrano Garrote Olga, Frontiñán Almudena Castro, Andreu Etelvina, Gutierrez-Vilchez Ana María, Anton-Bonete Marga, Martinez-Navarrete Gema, Castillo-Flores Nerea, Prat-Vidal Cristina, Blanco Margarita, Morante Valverde Rocío, Fernandez Eduardo, Querol Sergi, Hernández-Blasco Luis Manuel, Belda-Hofheinz Sylvia, Soria Bernat

СтатьяКлинический случайПеревод пока не подготовлен

Аннотация

BACKGROUND

Patients ineligible for lung transplant with end-stage Interstitial Lung Disease (ILD) on Extra-Corporeal Membrane Oxygenation (ECMO) face an appalling prognosis with limited therapeutic options. Due to the beneficial effect of Mesenchymal Stromal Cells (MSC) on inflammatory, immunological and infectious diseases, cell therapy has been proposed as an option, but administration is hampered by the ECMO.

METHODS

Cryopreserved Wharton-jelly derived MSC (WJ-MSC) were conveniently diluted and directly applied consecutively on each lobule (5,1 ml = 107 cells) at a continuous slow rate infused over one hour via flexible bronchoscopy (Consecutive IntraBronchial Administration method, CIBA method).

RESULTS

Intrabronchial administration of MSC to a patient on ECMO was well tolerated by the patient even though it did not reverse the patient's ILD. This manuscript presents preliminary evidence from ongoing clinical trials program on Cell Therapy of Inflammatory, Immune and Infectious Diseases and, to our knowledge, is the first report of intrabronchial administration of MSC in a paediatric ECMO patient with ILD. Even more, MSC administered by this method do not reach the systemic circulation and do get blocked on ECMO membrane.

CONCLUSIONS

Direct intrabronchial administration of MSC in a patient on ECMO is feasible and safe, and may be a new avenue to be assayed in ECMO patients with inflammatory, immunological and infectious diseases of the lung.

Для цитирования: Dominguez-Pinilla Nerea, González-Granado Luis Ignacio, Gonzaga Aitor, López Diaz María, Castellano Yáñez Cecilia, Aymerich Clara, Freire Xabier, Ordoñez Olga, Diaz de Atauri Álvaro Gimeno, Albi Rodríguez María Salomé, Martínez López Elisa, Iñiguez Rodrigo, Serrano Garrote Olga, Frontiñán Almudena Castro, Andreu Etelvina, Gutierrez-Vilchez Ana María, Anton-Bonete Marga, Martinez-Navarrete Gema, Castillo-Flores Nerea, Prat-Vidal Cristina, Blanco Margarita, Morante Valverde Rocío, Fernandez Eduardo, Querol Sergi, Hernández-Blasco Luis Manuel, Belda-Hofheinz Sylvia, Soria Bernat. Consecutive intrabronchial administration of Wharton's jelly-derived mesenchymal stromal cells in ECMO-supported pediatric patients with end-stage interstitial lung disease: a safety and feasibility study (CIBA method).. Stem cell research & therapy. 2025. DOI: 10.1186/s13287-025-04289-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.